Do Melanotan Peptides Give You a Safe Tan?
Melanotan products can darken skin, but the direct Melanotan II trial evidence is tiny. Online products may also contain a different dose from the label, while long-term safety remains poorly characterised. [1] [4] [5]
The claim being checked
Melanotan II injections or nasal sprays provide a safe and effective way to get a tan.
Melanotan II appears capable of increasing pigmentation, but the only direct controlled tanning study located involved three men. That is nowhere near enough to establish dependable cosmetic benefit or safety. Product testing and case reports add important concerns, but they cannot tell us the frequency of serious harms. [1] [8]
Overall evidence certainty: Very low for cosmetic Melanotan II use
Evidence at a glance
What melanotan peptides are
Melanotan I and Melanotan II are synthetic peptides related to alpha-melanocyte-stimulating hormone, a natural signal involved in pigment production. They are not interchangeable. Afamelanotide, a Melanotan I analogue, is a regulated implant used under specialist supervision for adults with erythropoietic protoporphyria (EPP), a rare condition that causes painful sensitivity to light. [17] [18]
Products sold online as Melanotan II are commonly marketed as injections or nasal sprays for tanning. The evidence for those consumer products is much thinner than the evidence for medically supervised afamelanotide.
What the best evidence says
Uncertain Melanotan II can increase skin pigmentation
A 1996 Phase I study alternated Melanotan II and saline injections in three healthy men. Two showed increased pigmentation after treatment. Nausea occurred at most dose levels, and spontaneous erections lasting one to five hours were reported. A study this small can show that a biological effect is possible, but it cannot establish how reliably the product works or how safe it is across a broader population. [1]
Uncertain Larger pigmentation studies support the idea, but used Melanotan I
Small Phase I studies found that Melanotan I increased tanning when combined with controlled ultraviolet exposure or sunlight. A randomised, double-blind study in 77 White adults also found increased melanin density compared with placebo. These findings support pigment production, but they do not establish the effectiveness or safety of Melanotan II injections and nasal sprays sold online. [2] [3]
Not supported Online products contain a reliable dose and acceptable purity
A laboratory analysis of products from three online shops found 4.32 to 8.84 mg of Melanotan II in vials labelled 10 mg. Unknown impurities reached 4.1% to 5.9% in products from two shops. [4]
In 2026, the Australian Therapeutic Goods Administration tested five nasal-spray bottles labelled 30 mg. The estimated amount ranged from 22 to 54 mg. The TGA states that Melanotan II is prescription-only in Australia, is not approved as a tanning agent, and has no product included in the Australian Register of Therapeutic Goods. [5]
Uncertain The frequency of serious harms
Reviews and case reports describe serious events after Melanotan II use, including rhabdomyolysis with kidney dysfunction, ischaemic priapism and renal infarction. Reports also describe rapid changes in moles and melanoma occurring around the time of melanotan use. [10] [11] [12] [13] [14]
Case reports are useful warning signals, but they cannot prove that melanotan caused every event or calculate how often these outcomes occur. Reviews of unregulated melanotans emphasise this uncertainty. [9]
Not supported A melanotan tan prevents skin cancer
Small Melanotan I studies measured pigmentation and short-term laboratory markers after ultraviolet exposure. They did not test whether cosmetic Melanotan II prevents melanoma or other skin cancers. No reliable clinical skin-cancer prevention evidence was located. [2]
Supported Regulated afamelanotide can help adults with EPP
Two randomised, double-blind trials enrolled 168 adults with EPP. A regulated 16 mg afamelanotide implant increased pain-free sunlight exposure compared with placebo. A systematic review also found a moderate positive effect for afamelanotide in this rare disease. [15] [16]
This does not validate online Melanotan II. The compound, formulation, dose, manufacturing controls, indication and medical supervision are different.
What this does not prove
- The available evidence does not show that every product marketed as Melanotan II contains the labelled ingredient or dose.
- The case reports do not prove that Melanotan II causes melanoma.
- The absence of large trials does not prove that every user will be harmed. It means uncommon and long-term risks are not adequately measured.
- Evidence for afamelanotide in adults with EPP cannot be transferred to cosmetic Melanotan II use.
- Increased pigmentation is not evidence of protection from skin cancer.
Safety and regulatory note
The central problem is not just side effects. It is uncertainty about both the drug and the product. The TGA has warned Australian consumers about melanotan tanning products and has documented inconsistent dosing in seized nasal sprays. The US Food and Drug Administration also identifies potential immunogenicity risks from aggregation and peptide-related impurities in compounded Melanotan II. [6] [7]
Key studies and sources
On mobile: swipe sideways to view all columns.
| Source | What it found | Main limitations |
|---|---|---|
| Dorr et al., 1996 Phase I controlled study, N=3 |
Two men developed increased pigmentation after Melanotan II dosing. Nausea, fatigue or somnolence, and prolonged spontaneous erections were reported. | Extremely small, male-only, short follow-up and not a nasal-spray study. |
| Fitzgerald et al., 2006 Randomised double-blind trial, N=77 |
Melanotan I increased melanin density compared with placebo. | Different peptide from Melanotan II; did not establish long-term cosmetic safety. |
| Breindahl et al., 2015 Laboratory product analysis |
Vials labelled 10 mg contained 4.32 to 8.84 mg; some contained 4.1% to 5.9% unknown impurities. | Products from only three online shops; older market sample. |
| TGA, 2026 Regulator testing, 5 bottles |
Nasal sprays labelled 30 mg contained an estimated 22 to 54 mg. | One seized product line; does not estimate inconsistency across the entire market. |
| Raza et al., 2026 Systematic review, 68 studies across tanning agents |
Mapped pigmentation methods and serious adverse-event reports linked with unregulated melanotans. | Mixed agents and study types; limited long-term melanotan data. |
| Habbema et al., 2017 Safety review |
Identified dosing, preparation and melanocytic-change concerns, including melanoma case reports. | Case reports cannot establish incidence or causal proof. |
| Langendonk et al., 2015 Two Phase III RCTs, N=168 |
Afamelanotide increased pain-free sunlight exposure in adults with EPP. | Industry-funded and indirect for cosmetic Melanotan II. |
Bottom line
Melanotan II probably can darken skin, but the direct human tanning evidence is based on only three participants. That is not enough to establish predictable benefit or acceptable safety. Current product testing also shows that some online injections and nasal sprays do not match their labels. A melanotan-induced tan should not be treated as proven protection from sunburn or skin cancer.
Frequently asked questions
Does Melanotan II make your skin darker?
It appears capable of increasing pigmentation, but the direct controlled Melanotan II tanning study located included only three men. Larger pigmentation studies used Melanotan I, a different peptide.
Are Melanotan II nasal sprays safe?
There is not enough reliable human evidence to establish their safety. The TGA has found inconsistent quantities of Melanotan II in sampled nasal-spray bottles, and long-term cosmetic safety trials are lacking.
Is Melanotan II approved for tanning in Australia?
No. The TGA states that Melanotan II is prescription-only, is not approved as a tanning agent, and has no product included in the Australian Register of Therapeutic Goods.
Does Melanotan II cause melanoma?
Melanoma and rapid mole changes have been reported around the time of melanotan use, but case reports cannot prove causation or estimate the level of risk. It would be inaccurate to claim either that melanoma causation is proven or that no risk exists.
Is afamelanotide the same as Melanotan II?
No. Afamelanotide is a regulated Melanotan I analogue used as a specialist-administered implant for adults with EPP. That evidence does not establish the safety of retail Melanotan II products.
Does a melanotan tan protect against skin cancer?
No reliable clinical evidence was located showing that cosmetic Melanotan II prevents melanoma or other skin cancers. Pigmentation should not be treated as proof of cancer protection.
References
- Dorr RT et al. Evaluation of melanotan-II in a pilot Phase I clinical study. 1996.
- Dorr RT et al. Melanotan I with ultraviolet radiation or sunlight in human volunteers. 2004.
- Fitzgerald LM et al. Effect of Melanotan I on melanin synthesis in people with MC1R variants. 2006.
- Breindahl T et al. Identification and characterisation of Melanotan II products sold online. 2015.
- Therapeutic Goods Administration. Melanotan II tanning peptide products found to be inconsistently dosed. 2026.
- Therapeutic Goods Administration. Do not risk using tanning products containing melanotan. 2025.
- US Food and Drug Administration. Bulk drug substances that may present significant safety risks.
- Raza et al. Insights into tanning biology and tanning products. 2026.
- Habbema L et al. Risks of unregulated alpha-melanocyte-stimulating hormone analogues. 2017.
- Nelson ME et al. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. 2012.
- Mallory CW et al. Melanotan tanning injection and acute ischaemic priapism. 2021.
- Wijkander M et al. Melanotan II as a possible cause of renal infarction. 2020.
- Reid C et al. Atypical melanocytic naevi following melanotan injection. 2013.
- Ong S, Bowling J. Melanotan-associated melanoma in situ. 2012.
- Langendonk JG et al. Afamelanotide for erythropoietic protoporphyria. 2015.
- Lala SM et al. Treatments for photosensitivity in EPP and X-linked protoporphyria: systematic review. 2022.
- US Food and Drug Administration. SCENESSE prescribing information. 2024.
- European Medicines Agency. SCENESSE European public assessment report.
Disclaimer
Disclaimer: This article is for general educational information only and is not medical advice. It does not diagnose, treat, or replace care from a qualified health professional. Always speak with a qualified health professional about personal health questions, medicines, pregnancy, medical conditions, or before changing treatment.
Melanotan II is not approved by the TGA as a tanning agent, and products sold online may not have been assessed for identity, strength, quality, safety or efficacy.
